348 related articles for article (PubMed ID: 31013934)
1. Structural Insights into CB1 Receptor Biased Signaling.
Al-Zoubi R; Morales P; Reggio PH
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013934
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.
Kargl J; Balenga N; Parzmair GP; Brown AJ; Heinemann A; Waldhoer M
J Biol Chem; 2012 Dec; 287(53):44234-48. PubMed ID: 23161546
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
4. Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex.
Krishna Kumar K; Shalev-Benami M; Robertson MJ; Hu H; Banister SD; Hollingsworth SA; Latorraca NR; Kato HE; Hilger D; Maeda S; Weis WI; Farrens DL; Dror RO; Malhotra SV; Kobilka BK; Skiniotis G
Cell; 2019 Jan; 176(3):448-458.e12. PubMed ID: 30639101
[TBL] [Abstract][Full Text] [Related]
5. CB1 Cannabinoid Receptor Signaling and Biased Signaling.
Leo LM; Abood ME
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500853
[TBL] [Abstract][Full Text] [Related]
6. Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors.
Soethoudt M; van Gils N; van der Stelt M; Heitman LH
Methods Mol Biol; 2016; 1412():103-11. PubMed ID: 27245896
[TBL] [Abstract][Full Text] [Related]
7. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.
Fay JF; Farrens DL
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912
[TBL] [Abstract][Full Text] [Related]
8. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor.
Hudson BD; Hébert TE; Kelly ME
Mol Pharmacol; 2010 Jan; 77(1):1-9. PubMed ID: 19837905
[TBL] [Abstract][Full Text] [Related]
9. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
[TBL] [Abstract][Full Text] [Related]
10. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
11. Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments.
Stornaiuolo M; Bruno A; Botta L; La Regina G; Cosconati S; Silvestri R; Marinelli L; Novellino E
Sci Rep; 2015 Oct; 5():15453. PubMed ID: 26482099
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
14. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
15. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
16. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
17. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
Gado F; Meini S; Bertini S; Digiacomo M; Macchia M; Manera C
Future Med Chem; 2019 Aug; 11(15):2019-2037. PubMed ID: 31517528
[TBL] [Abstract][Full Text] [Related]
18. Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential.
Seyedabadi M; Ghahremani MH; Albert PR
Pharmacol Ther; 2019 Aug; 200():148-178. PubMed ID: 31075355
[TBL] [Abstract][Full Text] [Related]
19. All-Atom Molecular Dynamics Simulations Indicated the Involvement of a Conserved Polar Signaling Channel in the Activation Mechanism of the Type I Cannabinoid Receptor.
Sarkar A; Mitra A; Borics A
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835641
[TBL] [Abstract][Full Text] [Related]
20. The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor.
Leo LM; Al-Zoubi R; Hurst DP; Stephan AP; Zhao P; Tilley DG; Miess E; Schulz S; Abood ME; Reggio PH
Cannabis Cannabinoid Res; 2023 Oct; 8(5):731-748. PubMed ID: 35792570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
